Finally, to investigate a potential transactivation of CAR T cells by tumor cells, we checked the expression of co-stimulatory ligands, such as CD70, 41BBL, CD80, and CD86, on BxPC-3 tumor cells by flow cytometry. This evidence concerns the gene CD86 and neoplasm.